Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446270) titled 'Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chinese PLA General Hospital
Condition:
Treatment for Advanced Colorectal Cancer
Treatment for Advanced Pancreatic Cancer
Intervention:
Drug: Colorectal cancer: Tunlametinib + cetuximab ß
Drug: Pancreatic cancer: Tunlametinib + cetuximab ß
Recruitment Status: Not rec...